拉米夫定联合水飞蓟宾治疗对E抗原阳性的慢性乙型肝炎患者相关血液指标的影响-论文.pdf

《拉米夫定联合水飞蓟宾治疗对E抗原阳性的慢性乙型肝炎患者相关血液指标的影响-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、国际检验医学杂志2014年7月第35卷第13期IntJLabMeal，July2014，Vo1．35，No．13·临床检验研究论著·拉米夫定联合水飞蓟宾治疗对E抗原阳性的慢性乙型肝炎患者相关血液指标的影响温庆辉，黎凤英，翟洁卿。，万德胜(广东省东莞市人民医院：1．检验科；2．信息科病案室；3．感染科，广东东莞523000)摘要：目的应用拉米夫定联合水飞蓟宾治疗E抗原阳性的慢性乙型肝炎，通过治疗前后的相关血液指标变化判断疗效，为个体化治疗提供依据。方法选取E抗原阳性慢性乙型肝炎患者226例，按肝功能损伤程度分为轻度组55例、中度组94例和重度组77例，均给予口服拉米夫定100mg，每

2、日1次及服用水飞蓟宾70mg，每日3次，疗程6个月。分别对治疗前后的相关血液指标进行分析。结果治疗6个月后，轻度组及中度组患者血清ALT复常率、E抗原阴转率及HBV—DNA阴转率有不同程度的改善，而重度组上述指标则均显著提高(P

3、)13-1720—02EffectoflamivudinecombinedwithsilibinintreatmentonrelatedbloodindexesinpatientswithEantigenpositivechronichepatitisBWenQinghui，LiFengying，ZhaiJieqing。，WanDesheng(1．DepatmentofClinicalLaboratory；2．MedicalRecordsRoomDepartmentofInformation；3．Departmentofj”fection，DongguanMunicipalPeop

4、leSHospital，Dongguan，Guangdong523000，China)Abstract：ObjectiveTojudgetheeffectbyunderstandingthechangeofthebloodrelatedindexesbeforeandaftertheapplica—tionoflamivudinecombinedwithsilibinintreatmentfortreatingEantigenpositivechronichepatitisBtOprovidethebasisfortheindividualizedtherapy．Methods22

5、6casesofEantigenpositivechronichepatitisBwereselectedanddividedintothemildgroup(55cases)，moderategroup(94cases)andseveregroup(77cases)accordingtothedegreeof1iverfunctioninjury．The3groupsweregivenorallamivudine100mgoncedailyandoralsilybinin70mg，3timesaday．Thecourseoftreatmentwas6months；there—la

6、tedbloodindexesbeforeandaftertreatmentwereanalyzed．ResultsAfter6monthsoftreatment，therecoveryrateofALT，Ean—tigennegativeconversionrateandHBV—DNAnegativeconversionrateinthemildgroupandthemoderategroupwereimprovedindifferentdegrees，andthoseintheseveregroupweresignificantlyincreased(P~0．05)．Concl

7、usionLamivudinecombinedwithsili—binintreatmentcaninhibitthereplicationofHBV—DNAmoreeffectively，promotetherecoveryrateofserumALTsignificantly．im—provetheEantigennegativeconversionrate，especiallyforthepatientswithsevere1iverfunctioninjury